Anthony Chalmers
Professor & Clinical Oncology Chair University of Glasgow
Seminars
• Pioneering a novel approach to dose escalation in radiotherapy–DDR inhibitor trials that reduce delays by testing multiple agents in parallel
• Applying adaptive statistical methods enabling faster determination of safe, effective doses
• Extending early data from lung cancer studies to brain tumors and other hard-to-treat cancers
• Presenting phase I data on radiotherapy with PARP inhibitors (olaparib, niraparib) across diverse GBM patient populations
• Detailing insights from first-in-human radiotherapy + ATM inhibitor studies advancing into randomized phase II/III trials
• Affirming preclinical evidence that PARP and ATM inhibitors both radiosensitize GBM tumors and protect healthy brain tissue from radiation-induced cognitive decline
